Zai Lab Shares Rise After Launching Phase 3 Lung Cancer Drug Trial

Shares of Zai Lab (09688.HK) rose in early trading on the Hong Kong Stock Exchange following news that the company has initiated a pivotal late-stage clinical trial for a potential cancer therapy. The development marks a key step forward for the company's internally developed drug pipeline.

Market Reaction

The company's stock climbed nearly 5% during morning trading. According to a report from Zhitong Finance App, the shares were last trading up 3.60% at HK$20.14, with a turnover of HK$15.86 million.

The positive investor sentiment reflects the significance of advancing a proprietary drug candidate into a global Phase 3 study, a crucial step before seeking regulatory approval. Zai Lab also trades in the U.S. via American Depositary Receipts (ZLAB).

Clinical Trial Details

The catalyst for the stock's move was the registration of a global Phase 3 clinical trial for ZL-1310, filed on Clinicaltrials.gov on August 31. ZL-1310 is an antibody-drug conjugate (ADC) that targets a protein known as DLL3.

Ad

The study will evaluate the drug's efficacy and safety as a first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC) when used in combination with a PD-L1 inhibitor. Key details of the trial include:

• Patient Population: The trial aims to enroll 530 patients with previously untreated ES-SCLC.
• Study Design: A global, multi-center Phase 3 trial.
• Projected Timeline: The preliminary completion date is estimated for June 2030, as per the clinical trial registration.

Analyst Outlook

This clinical advancement aligns with recent analyst commentary on the company's pipeline. A report from China Securities noted that Zai Lab's self-developed assets are entering a critical phase of clinical validation, with several key catalysts expected in the second half of the year.

Analysts are watching for upcoming data readouts and regulatory progress for ZL-1310 in both SCLC and other neuroendocrine cancers. The firm also anticipates the release of first-in-human data for another pipeline candidate, ZL-1503, an antibody for inflammatory diseases.